• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Iso-osmolar agent showshigher renal failure rate

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 31 No 1
Volume 31
Issue 1

Radiologists hoped the introduction of isoosmolarcontrast media would eliminatesevere adverse reactions to x-ray contrast.Alas, it was not to be.

Radiologists hoped the introduction of isoosmolar contrast media would eliminate severe adverse reactions to x-ray contrast. Alas, it was not to be. A large retrospective Swedish study identified a significantly higher rate of renal failure among patients administered iso-osmolar iodixanol (Visipaque) compared with patients who received low-osmolar ioxaglate (Hexabrix).

Dr. Per Liss and colleagues at the University of Uppsala presented their evaluation of 23,224 patients at the 2008 RSNA meeting. They found that 1.7% of patients who received iodixanol developed primary or secondary renal failure within 12 months of administration. The 12-month renal failure rate for patients who received ioxaglate was 0.8%.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.